1 |
<p align="center"><b>PLIVA Krakow Zakladi Farmaceutyczne S.A, a subsidiary of |
2 |
PLIVA d. d. Zagreb, applied for price approval for the product Virlix® 10mg*20tab. |
3 |
(cetirizine)</b></p> |
4 |
<p>PLIVA Krakow has applied for price approval of the drug Virlix® 10mg*20tab. |
5 |
(cetirizine) which will replace the product Zyrtec® 10mg*20tab. (cetirizine) |
6 |
in PLIVA Krakows product portfolio.</p> |
7 |
<p>Both drugs are licensed products of UCB, and while UCB will take over the sales |
8 |
of Zyrtec® 10mg*20tab., PLIVA Krakow will market cetirizine under the trademark</p> |
9 |
<p>Virlix® 10mg*20tab. Virlix® 10mg*20tab. has already been registered, listed |
10 |
on the reimbursement list and is expected to be launched soon on the Polish |
11 |
market.</p> |
12 |
<p>In addition to cetirizine, PLIVA and UCB have earlier signed collaboration |
13 |
agreements for the products Mistabron® amp. 600 mg (mesna, a respiratory drug) |
14 |
and Nootropil® 400 mg (piracetam, nootropic). </p> |